Deepika Polineni, M.D., MPH
Assistant Professor of Internal Medicine in the Division of Pulmonary and Critical Care Medicine at the University of Kansas Medical Center
Dr. Deepika Polineni is an Assistant Professor of Internal Medicine in the Division of Pulmonary and Critical Care Medicine at the University of Kansas Medical Center.
She received her Bachelor of Arts and Doctor of Medicine degrees from the University of Missouri, Kansas City, as well as Master of Public Health degree from Boston University. She completed residency in Internal Medicine at the University of Michigan Ann Arbor, fellowship in Pulmonary Medicine at the University of North Carolina at Chapel Hill, and post-doctoral research in pulmonary medicine at Washington University in St. Louis.
Dr. Polineni's research interests include the identification of non-CFTR genetic modifiers of cystic fibrosis (CF) lung disease, as well as developing methods for improving treatment adherence in CF. Her long-standing research focus has been in-vivo transcriptomic and metabolomic studies to identify differential gene expression and metabolite variability associated with CF lung disease severity. These studies are complementary to ongoing genomic studies of the North American CF Modifiers Consortium, with the goal of advancing personalized CF therapies. She has also begun a multi-center clinical trial to study novel tele-communication based methods aimed at improving patient adherence to complex CF treatment regimens. Dr. Polineni's clinical interests include cystic fibrosis, primary ciliary dyskinesia, and non-CF bronchiectasis.
She serves as the associate adult program director for the University of Kansas Cystic Fibrosis Care Center, and director for the University of Kansas & Children's Mercy Hospital Primary Ciliary Dyskinesia Clinical Center. She additionally serves as co-investigator for the University of Kansas Cystic Fibrosis Foundation Therapeutics Development Network grant, conducting clinical trials to evaluate the safety and effectiveness of new CF therapies.
She is a member of the American Thoracic Society, American College of Chest Physicians, and has served as a member of the Scientific Advisory Committee for the American Lung Association since 2013.
Media who are interested in scheduling an interview with Dr. Polineni may contact Media@Lung.org.